Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Macular Degeneration HELP
Based on 12,795 articles published since 2007

These are the 12795 published articles about Macular Degeneration that originated from Worldwide during 2007-2017.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. 2017

Tuuminen, Raimo / Uusitalo-Järvinen, Hannele / Aaltonen, Vesa / Hautala, Nina / Kaipiainen, Sulevi / Laitamäki, Nina / Ollila, Marko / Rantanen, Jari / Välimäki, Satu / Sipilä, Raija / Laukkala, Tanja / Komulainen, Jorma / Tommila, Petri / Immonen, Ilkka / Tuulonen, Anja / Kaarniranta, Kai. ·Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland.; Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.; Patient Insurance Centre, Helsinki, Finland. · Tays Eye Centre, Tampere University Hospital, Tampere, Finland. · Department of Ophthalmology, Turku University Hospital, Turku, Finland. · Department of Ophthalmology, Oulu University Hospital, Oulu, Finland.; Medical Research Center, University of Oulu, Oulu, Finland. · Department of Ophthalmology, North Karelian Central Hospital, Joensuu, Finland. · Department of Ophthalmology, Kanta-Häme Central Hospital, Hämeenlinna, Finland. · Department of Ophthalmology, Lapland Central Hospital, Rovaniemi, Finland. · Department of Ophthalmology, Satakunta Central Hospital, Pori, Finland. · Department of Ophthalmology, Päijät-Häme Central Hospital, Lahti, Finland. · The Finnish Medical Society Duodecim, Helsinki, Finland. · Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland. · Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland.; Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ·Acta Ophthalmol · Pubmed #28686003.

ABSTRACT: Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of society and of the healthcare system poses challenges for the provision and development of care. In context of these current aspects, we aimed to set evidence-based medical guidelines for diagnosis, treatment and follow-up of patients with wAMD.

2 Guideline Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. 2017

Gale, R / Scanlon, P H / Evans, M / Ghanchi, F / Yang, Y / Silvestri, G / Freeman, M / Maisey, A / Napier, J. ·The Action on DMO group, UK.; The York Hospital, York, UK. · The Action on DMO group, UK.; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. · The Action on DMO group, UK.; University Hospital, Llandough, Cardiff, UK. · The Action on DMO group, UK.; Bradford Teaching Hospitals, Bradford, UK. · The Action on DMO group, UK.; The Royal Wolverhampton NHS Trust, Wolverhampton, UK. · The Action on DMO group, UK.; Belfast Health & Social Care Trust, Belfast, UK. · The Action on DMO group, UK.; Royal Hallamshire Hospital, Sheffield, UK. · The Action on DMO group, UK.; Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. · The Action on DMO group, UK.; Bayer, Reading, UK. ·Eye (Lond) · Pubmed #28490797.

ABSTRACT: This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients' views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.

3 Guideline Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. 2017

Holz, Frank G / Sadda, SriniVas R / Staurenghi, Giovanni / Lindner, Moritz / Bird, Alan C / Blodi, Barbara A / Bottoni, Ferdinando / Chakravarthy, Usha / Chew, Emily Y / Csaky, Karl / Curcio, Christine A / Danis, Ron / Fleckenstein, Monika / Freund, K Bailey / Grunwald, Juan / Guymer, Robyn / Hoyng, Carel B / Jaffe, Glenn J / Liakopoulos, Sandra / Monés, Jordi M / Oishi, Akio / Pauleikhoff, Daniel / Rosenfeld, Philip J / Sarraf, David / Spaide, Richard F / Tadayoni, Ramin / Tufail, Adnan / Wolf, Sebastian / Schmitz-Valckenberg, Steffen / Anonymous8780894. ·Department of Ophthalmology, University of Bonn, Bonn, Germany. Electronic address: Frank.Holz@ukb.uni-bonn.de. · Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California. · Eye Clinic, Department of Biomedical and Clinical Sciences "Luigi Sacco," Luigi Sacco Hospital, University of Milan, Milan, Italy. · Department of Ophthalmology, University of Bonn, Bonn, Germany. · Institute of Ophthalmology, University College London, London, United Kingdom. · Department of Ophthalmology and Visual Sciences, Fundus Photograph Reading Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. · Institute of Clinical Science, The Queen's University of Belfast, Belfast, United Kingdom. · National Eye Institute, National Institutes of Health, Bethesda, Maryland. · Texas Retina Associates, Dallas, Texas. · Department of Ophthalmology, University of Alabama School of Medicine, Birmingham, Alabama. · Vitreous Retina Macula Consultants of New York, New York, New York. · Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. · Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Department of Surgery (Ophthalmology) Melbourne, Australia. · Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands. · Department of Ophthalmology, Duke Reading Center, Duke University, Durham, North Carolina. · Department of Ophthalmology, Cologne Image Reading Center, University of Cologne, Cologne, Germany. · Institut de la Màcula and Barcelona Macula Foundation, Barcelona, Spain. · Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany. · Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. · Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, California. · Ophthalmology Department, Hôpital Lariboisière, AP-HP, Université Paris 7 - Sorbonne Paris Cité, Paris, France. · Moorfields Eye Hospital, London, United Kingdom. · Department of Ophthalmology, University Hospital Bern, University of Bern, Bern, Switzerland. · ·Ophthalmology · Pubmed #28109563.

ABSTRACT: PURPOSE: To summarize the results of 2 consensus meetings (Classification of Atrophy Meeting [CAM]) on conventional and advanced imaging modalities used to detect and quantify atrophy due to late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendations on the use of these modalities in natural history studies and interventional clinical trials. DESIGN: Systematic debate on the relevance of distinct imaging modalities held in 2 consensus meetings. PARTICIPANTS: A panel of retina specialists. METHODS: During the CAM, a consortium of international experts evaluated the advantages and disadvantages of various imaging modalities on the basis of the collective analysis of a large series of clinical cases. A systematic discussion on the role of each modality in future studies in non-neovascular and neovascular AMD was held. MAIN OUTCOME MEASURES: Advantages and disadvantages of current retinal imaging technologies and recommendations for their use in advanced AMD trials. RESULTS: Imaging protocols to detect, quantify, and monitor progression of atrophy should include color fundus photography (CFP), confocal fundus autofluorescence (FAF), confocal near-infrared reflectance (NIR), and high-resolution optical coherence tomography volume scans. These images should be acquired at regular intervals throughout the study. In studies of non-neovascular AMD (without evident signs of active or regressed neovascularization [NV] at baseline), CFP may be sufficient at baseline and end-of-study visit. Fluorescein angiography (FA) may become necessary to evaluate for NV at any visit during the study. Indocyanine-green angiography (ICG-A) may be considered at baseline under certain conditions. For studies in patients with neovascular AMD, increased need for visualization of the vasculature must be taken into account. Accordingly, these studies should include FA (recommended at baseline and selected follow-up visits) and ICG-A under certain conditions. CONCLUSIONS: A multimodal imaging approach is recommended in clinical studies for the optimal detection and measurement of atrophy and its associated features. Specific validation studies will be necessary to determine the best combination of imaging modalities, and these recommendations will need to be updated as new imaging technologies become available in the future.

4 Guideline Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. 2016

Puliafito, Carmen A / Cousins, Scott W / Bacharach, Jason / Gonzalez, Victor H / Holekamp, Nancy M / Merrill, Pauline T / Ohr, Matthew P / Parrish, Richard K / Riemann, Christopher D. · ·Ophthalmic Surg Lasers Imaging Retina · Pubmed #27096289.

ABSTRACT: The diabetic macular edema (DME) treatment paradigm has evolved as the understanding of the disease pathology has grown. Since 2012, four pharmacotherapies have been approved by the U.S. Food and Drug Administration for the treatment of DME. First-line treatment of DME with anti-vascular endothelial growth factor [VEGF] agents has become the gold standard; however, an appreciable percentage of patients do not respond to anti-VEGF therapies. In patients who inadequately respond to anti-VEGF therapies, the underlying disease pathology may be mediated by a multitude of growth factors and inflammatory cytokines. For these patients, corticosteroids are an attractive treatment option because they not only downregulate VEGF, but also an array of cytokines. The phase 3 MEAD and FAME trials demonstrated significant visual acuity improvements associated with dexamethasone and fluocinolone acetonide, respectively, in patients with DME; however, class-specific adverse events, including increased intraocular pressure and cataract development, must be considered before use. A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology for a roundtable discussion focused on patient selection and adverse event management associated with the use of the 0.19 mg fluocinolone acetonide intravitreal implant.

5 Guideline Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement. 2016

Anonymous2930860 / Siu, Albert L / Bibbins-Domingo, Kirsten / Grossman, David C / Baumann, Linda Ciofu / Davidson, Karina W / Ebell, Mark / García, Francisco A R / Gillman, Matthew / Herzstein, Jessica / Kemper, Alex R / Krist, Alex H / Kurth, Ann E / Owens, Douglas K / Phillips, William R / Phipps, Maureen G / Pignone, Michael P. · · Mount Sinai School of Medicine, New York2James J. Peters Veterans Affairs Medical Center, Bronx, New York. · University of California, San Francisco. · Group Health Research Institute, Seattle, Washington. · University of Wisconsin, Madison. · Columbia University, New York, New York. · University of Georgia, Athens. · Pima County Department of Health, Tucson, Arizona. · Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts. · Independent consultant, Washington, DC. · Duke University, Durham, North Carolina. · Fairfax Family Practice, Fairfax, Virginia13Virginia Commonwealth University, Richmond. · New York University, New York. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California16Stanford University, Stanford, California. · University of Washington, Seattle. · Brown University, Providence, Rhode Island. · University of North Carolina, Chapel Hill. ·JAMA · Pubmed #26934260.

ABSTRACT: DESCRIPTION: Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults. METHODS: The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration. POPULATION: This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement).

6 Guideline Recommendations for the appropriate management of diabetic macular edema: Light on DME survey and consensus document by an expert panel. 2016

Bandello, Francesco / Midena, Edoardo / Menchini, Ugo / Lanzetta, Paolo. ·Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan - Italy. · Department of Neuroscience-Ophthalmology, University of Padova, Padova - Italy. · University of Florence, Clinica Oculistica AOU Careggi, Florence - Italy. · Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy.; Istituto Europeo di Microchirurgia Oculare, Udine - Italy. ·Eur J Ophthalmol · Pubmed #26776698.

ABSTRACT: PURPOSE: The Light on DME survey was designed to address several issues concerning the management of diabetic macular edema (DME) with the objective of producing practical recommendations for the appropriate treatment of this condition. METHODS: The recommendations considered aspects of DME treatment that are controversial and insufficiently supported by the evidence and were based on a consensus reached by an expert panel. Consensus was achieved by means of the Delphi method. Thirty-one Italian retinologists were asked to rate the appropriateness of a comprehensive set of scenarios typically encountered in the management of DME in clinical practice. The results of the appropriateness evaluation were analyzed by the study panel and a second assessment round was conducted for those scenarios on which no consensus was reached. RESULTS: Consensus was reached on several relevant aspects of current DME management, namely the initiation and course of treatment with anti-vascular endothelial growth factor (VEGF) therapy, assessment of the outcomes of anti-VEGF therapy based on both functional and morphologic outcomes, combination of anti-VEGF with laser therapy, and management of nonresponders to anti-VEGFs. A few issues, including the definition of DME based on novel diagnostic tools, the need for stable metabolic parameters before initiating anti-VEGF therapy, and the use of a second anti-VEFG after failure of the first anti-VEGF, proved controversial. CONCLUSIONS: A clear consensus among DME experts was reached on several relevant aspects of DME management. Based on this consensus, detailed and practical recommendations to guide ophthalmologists in the use of novel approaches to DME could be developed.

7 Guideline [Not Available]. 2015

Anonymous4640852 / Anonymous4650852 / Anonymous4660852. · ·Klin Monbl Augenheilkd · Pubmed #26678907.

ABSTRACT: -- No abstract --

8 Guideline [Diabetic macular edema: Diagnosis and pre-treatment work-up]. 2015

Massin, P / Baillif, S / Creuzot, C / Fajnkuchen, F / Kodjikian, L / Anonymous1550847. ·Cabinet d'ophtalmologie Breteuil, hôpital Lariboisière, AP-HP, université Paris Diderot, 14, avenue de Breteuil, 75007 Paris, France. Electronic address: massin.breteuil@gmail.com. · Hôpital Pasteur 2, CHU de Nice, université Nice - Sofia-Antipolis, 30, voie Romaine, 06000 Nice, France. · CHU de Dijon, université de Bourgogne, 14, rue Paul-Gaffarel, 21079 Dijon, France. · Centre d'imagerie et de laser, hôpital Avicenne, Bobigny - Paris XIII, 11, rue Antoine-Bourdelle, 75015 Paris, France. · CHU de la Croix-Rousse, hospices civils de Lyon, université Claude-Bernard - Lyon I, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France. · ·J Fr Ophtalmol · Pubmed #26507784.

ABSTRACT: -- No abstract --

9 Guideline [Physician information sheet: Treatment of diabetic macular edema]. 2015

Massin, P / Baillif, S / Creuzot, C / Fajnkuchen, F / Kodjikian, L / Anonymous6780846. ·Cabinet d'ophtalmologie Breteuil, 14, avenue de Breteuil, 75007 Paris, France; Hôpital Lariboisière, université Paris Diderot, AP-HP, 2, rue Ambroise-Paré, 75010 Paris, France. Electronic address: massin.breteuil@gmail.com. · Hôpital Pasteur 2, université de Nice Sofia-Antipolis, CHU de Nice, 30, voie Romaine, 06000 Nice, France. · Université de Bourgogne, CHU de Dijon, 14, rue Paul-Gaffarel, 21079 Dijon, France. · Centre d'imagerie et de laser, hôpital Avicenne, Bobigny Paris XIII, 11, rue Antoine-Bourdelle, 75015 Paris, France. · Hospices civils de Lyon, université Claude-Bernard Lyon I, CHU de la Croix-Rousse, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France. · ·J Fr Ophtalmol · Pubmed #26494496.

ABSTRACT: -- No abstract --

10 Guideline TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. 2015

Freund, K Bailey / Korobelnik, Jean-François / Devenyi, Robert / Framme, Carsten / Galic, John / Herbert, Edward / Hoerauf, Hans / Lanzetta, Paolo / Michels, Stephan / Mitchell, Paul / Monés, Jordi / Regillo, Carl / Tadayoni, Ramin / Talks, James / Wolf, Sebastian. ·*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland. · ·Retina · Pubmed #26076215.

ABSTRACT: PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti-vascular endothelial growth factor agents, considering factors such as criteria for extension. RESULTS: A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography-guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti-vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. CONCLUSION: It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases.

11 Guideline Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). 2014

Schmidt-Erfurth, Ursula / Chong, Victor / Loewenstein, Anat / Larsen, Michael / Souied, Eric / Schlingemann, Reinier / Eldem, Bora / Monés, Jordi / Richard, Gisbert / Bandello, Francesco / Anonymous5650803. ·Department of Ophthalmology, Medical University, Vienna, Austria. · Oxford Eye Hospital, Oxford University Hospitals, Oxford, UK. · Department of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel. · Department of Ophthalmology, Glostrup Hospital and University of Copenhagen, Copenhagen, Denmark. · Hôpital Intercommunal de Créteil, Paris, France. · Medical Retina Unit and Ocular Angiogenesis Group, Department Of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands. · Department of Ophthalmology, Hacettepe University, School of Medicine, Ankara, Turkey. · Centro Médico TEKNON, Director Institut de la Màcula i de la Retina, Barcelona, Spain. · Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Ophthalmology, University Vita-Salute; Scientific Institute San Raffaele, Milano, Italy. · ·Br J Ophthalmol · Pubmed #25136079.


12 Guideline [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014]. 2014

Heiligenhaus, A / Bertram, B / Heinz, C / Krause, L / Pleyer, U / Roider, J / Sauer, S / Thurau, S / Anonymous2660803 / Anonymous2670803 / Anonymous2680803. ·Augenabteilung, St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland, arnd.heiligenhaus@uveitis-zentrum.de. · ·Ophthalmologe · Pubmed #25118844.

ABSTRACT: -- No abstract --

13 Guideline Management paradigms for diabetic macular edema. 2014

Mitchell, Paul / Wong, Tien Yin / Anonymous4590776. ·Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia. · Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore. Electronic address: ophwty@nus.edu.sg. · ·Am J Ophthalmol · Pubmed #24269850.

ABSTRACT: PURPOSE: To provide evidence-based recommendations for diabetic macular edema (DME) management based on updated information from publications on DME treatment modalities. DESIGN: Perspective. METHODS: A literature search for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Library, and ClinicalTrials.gov databases to identify studies from January 1, 1985 to July 31, 2013. Meta-analyses, systematic reviews, and randomized controlled trials with at least 1 year of follow-up published in the past 5 years were preferred sources. RESULTS: Although laser photocoagulation has been the standard treatment for DME for nearly 3 decades, there is increasing evidence that superior outcomes can be achieved with anti-vascular endothelial growth factor (anti-VEGF) therapy. Data providing the most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated visual improvement and favorable safety profile for up to 3 years. Average best-corrected visual acuity change from baseline ranged from 6.1-10.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for ranibizumab, compared to 1.4-5.9 ETDRS letters with laser. The proportion of patients gaining ≥ 10 or ≥ 15 letters with ranibizumab was at least 2 times higher than that of patients treated with laser. Patients were also more likely to experience visual loss with laser than with ranibizumab treatment. Ranibizumab was generally well tolerated in all studies. Studies for bevacizumab, aflibercept, and pegaptanib in DME were limited but also in favor of anti-VEGF therapy over laser. CONCLUSIONS: Anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe visual impairment caused by DME.

14 Guideline Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance. 2014

Hooper, Philip / Boucher, Marie-Carole / Colleaux, Kevin / Cruess, Alan / Greve, Mark / Lam, Wai-Ching / Shortt, Stanley / Tourville, Eric. ·Western University, London, Ont., Canada. · ·Ophthalmologica · Pubmed #24246998.

ABSTRACT: Recent advances in the therapeutic options and approaches for diabetic retinopathy (DR) and diabetic macular edema (DME) have resulted in improved visual outcomes for many patients with diabetes. Yet, they have also created many clinical dilemmas for treating ophthalmologists and retina specialists, including treatment selection, initiation, frequency and duration. With this in mind, a panel of Canadian retina specialists met and discussed the current clinical evidence as well as specific situations and scenarios commonly encountered in daily practice. They also shared their experiences and therapeutic approaches. This document, containing a consensus on treatment algorithms for various clinical scenarios, is the result of their lengthy and in-depth discussions and considerations. The intent is to provide a step-by-step approach to the treatment of DR and DME. Although clinicians are encouraged to use and refer to these algorithms as a guide for various situations, they are not meant to be a replacement for sound clinical judgment.

15 Guideline The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. 2013

Chakravarthy, U / Williams, M / Anonymous2850773. ·Department of Ophthalmology, Queen's University Belfast, Belfast, UK. · ·Eye (Lond) · Pubmed #24158023.

ABSTRACT: -- No abstract --

16 Guideline [Age-related macular degeneration]. 2013

Conselho Brasileiro de Oftalmologia, ?. ·Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil. diretrizes@amb.org.br ·Rev Assoc Med Bras (1992) · Pubmed #23582550.

ABSTRACT: -- No abstract --

17 Guideline [Statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies]. 2012

Anonymous5190734 / Anonymous5200734 / Anonymous5210734. · ·Ophthalmologe · Pubmed #22911358.

ABSTRACT: -- No abstract --

18 Guideline [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis]. 2012

Anonymous2790716 / Anonymous2800716 / Anonymous2810716. · ·Ophthalmologe · Pubmed #22274298.

ABSTRACT: -- No abstract --

19 Guideline [Intravitreal injections: AFSSAPS guide to good practice]. 2012

Bodaghi, B / Korobelnik, J F / Cochereau, I / Hajjar, J / Goebel, F / Dumarcet, N / Anonymous5870714. ·Service d'Ophtalmologie, Assistance-Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Université Pierre et Marie Curie, 47-83 bd de l'Hôpital, 75013, Paris, France. bahram.bodaghi@psl.aphp.fr · ·J Fr Ophtalmol · Pubmed #22226388.

ABSTRACT: Intravitreal injections are very commonly performed in the daily practice of Ophthalmology and become a leading procedure in the management of age-related macular degeneration, diabetic retinopathy, infectious endophthalmitis or retinitis, uveitis and retinal vein occlusions. Based on the comments of a group of experts, including ophthalmologists, pharmacists and hygienists, the French Agency for the Safety of Health Products (AFSSAPS) edited a guide to good practice of intravitreal injections, revisiting those previously published in 2006. The overall experience accumulated during time is a valuable source of information to determine the most appropriate protocol. Therefore, the simplification of the procedure is reasonably proposed even though safety remains a major issue, in order to avoid complications, especially infections.

20 Guideline Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. 2011

Anonymous1010712 / Anonymous1020712 / Aiello, Lloyd Paul / Beck, Roy W / Bressler, Neil M / Browning, David J / Chalam, K V / Davis, Matthew / Ferris, Frederick L / Glassman, Adam R / Maturi, Raj K / Stockdale, Cynthia R / Topping, Trexler M. ·Department of Ophthalmology, Harvard Medical School, Joslin Diabetes Center, Boston, Massachusetts, USA. · ·Ophthalmology · Pubmed #22136692.

ABSTRACT: OBJECTIVE: To describe the underlying principles used to develop a web-based algorithm that incorporated intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in a Diabetic Retinopathy Clinical Research Network (DRCR.net) randomized clinical trial. DESIGN: Discussion of treatment protocol for DME. PARTICIPANTS: Subjects with vision loss resulting from DME involving the center of the macula. METHODS: The DRCR.net created an algorithm incorporating anti-VEGF injections in a comparative effectiveness randomized clinical trial evaluating intravitreal ranibizumab with prompt or deferred (≥24 weeks) focal/grid laser treatment in eyes with vision loss resulting from center-involved DME. Results confirmed that intravitreal ranibizumab with prompt or deferred laser provides superior visual acuity outcomes compared with prompt laser alone through at least 2 years. Duplication of this algorithm may not be practical for clinical practice. To share their opinion on how ophthalmologists might emulate the study protocol, participating DRCR.net investigators developed guidelines based on the algorithm's underlying rationale. MAIN OUTCOME MEASURES: Clinical guidelines based on a DRCR.net protocol. RESULTS: The treatment protocol required real-time feedback from a web-based data entry system for intravitreal injections, focal/grid laser treatment, and follow-up intervals. Guidance from this system indicated whether treatment was required or given at investigator discretion and when follow-up should be scheduled. Clinical treatment guidelines, based on the underlying clinical rationale of the DRCR.net protocol, include repeating treatment monthly as long as there is improvement in edema compared with the previous month or until the retina is no longer thickened. If thickening recurs or worsens after discontinuing treatment, treatment is resumed. CONCLUSIONS: Duplication of the approach used in the DRCR.net randomized clinical trial to treat DME involving the center of the macula with intravitreal ranibizumab may not be practical in clinical practice, but likely can be emulated based on an understanding of the underlying rationale for the study protocol. Inherent differences between a web-based treatment algorithm and a clinical approach may lead to differences in outcomes that are impossible to predict. The closer the clinical approach is to the algorithm used in the study, the more likely the outcomes will be similar to those published. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

21 Guideline [SERV clinical practice guidelines: management of retinal vein occlusion. Sociedad Española de Retina y Vitreo]. 2010

Gómez-Ulla, F / Abraldes, M J / Basauri, E / Fernández, M / García-Layana, A / Gili, P / Montero, J / Nadal, J / Morales, V / Saravia, M / Cabrera, F / Cervera, E / Anonymous6190681. ·Complejo Hospitalario Universitario de Santiago de Compostela, Instituto Tecnológico de Oftalmología, Santiago de Compostela, España. · ·Arch Soc Esp Oftalmol · Pubmed #21167436.

ABSTRACT: PURPOSE: A guidelines for the management of retinal vein occlusion is presented. This is necessary because at this moment several therapeutic alternatives have been developed although their role is not yet sufficiently defined. METHODS: Review of the literature for evidence published up to date. Relevant literature was identified and the level of evidence graded. Evidence was then assessed for consistency, applicability and clinical impact. The information was contrasted with those guides published in other countries. RESULTS: Taking into account the different options of treatment that are currently used, several modes of action are suggested. The role of the various complementary examinations are discussed and it is recommended that criteria for the treatment are based on clinical, angiographic, and tomographic findings. CONCLUSIONS: Although there is no overall consensus, these guidelines promote a good standard of clinical practise and provide an update of the management of retinal vein occlusion.

22 Guideline [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on Therapy for Macular Oedema in Cases of Retinal Vein Occlusion]. 2010

Anonymous1170666 / Anonymous1180666 / Anonymous1190666. · ·Klin Monbl Augenheilkd · Pubmed #20645226.

ABSTRACT: -- No abstract --

23 Guideline [Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. 2009

Pareja-Ríos, A / Serrano-García, M A / Marrero-Saavedra, M D / Abraldes-López, V M / Reyes-Rodríguez, M A / Cabrera-López, F / López-Gálvez, M / Cardona-Guerra, P / Abreu-Reyes, P / Quijada-Fumero, E / Coronado-Toural, A / Gutiérrez-Sánchez, E / Gil-Hernández, M A / Valls-Quintana, P / Marín-Olmos, F / Navarro-Alemany, R. ·Hospital Universitario de Canarias, La Laguna, Tenerife, España. aparejar@gmail.com · ·Arch Soc Esp Oftalmol · Pubmed #19809923.

ABSTRACT: OBJECTIVE: Diabetes mellitus is considered the most common cause of blindness in the working population of industrialized countries, with diabetic macular edema being the most common cause of decreased visual acuity and proliferative diabetic retinopathy (PDR) being responsible for the most severe visual deficits. We have therefore tried to establish a guide for clinical intervention whose purpose is to provide orientation on the treatment of diabetic retinopathy and its complications. This is necessary at a time when many treatment options have emerged whose role is not yet fully defined. METHOD: A group of expert retina specialists selected by the SERV (Vitreous-Retina Spanish Society) assessed the published results of different treatment options currently available, suggesting lines of action according to the degree of diabetic retinopathy present and the presence or absence of macular edema. RESULTS: PDR is primarily treated with pan-retinal photocoagulation. For clinically significant diabetic macular edema without signs of vitreomacular traction, the treatment of choice continues to be focal/grid photocoagulation. Similarly, retinovitreal surgery is indicated for both conditions. The use of antiangiogenic drugs was also analyzed but remains inconclusive. CONCLUSION: Laser therapy is effective in the management of diabetic retinopathy and diabetic macular edema. The role of antiangiogenics is not yet sufficiently defined.

24 Guideline [Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD)]. 2009

Ruiz-Moreno, J M / Arias-Barquet, L / Armadá-Maresca, F / Boixadera-Espax, A / García-Layana, A / Gómez-Ulla-de-Irazazábal, F / Monés-Carilla, J / Piñero-Bustamante, A / Suárez-de-Figueroa, M / Anonymous3510635. ·Catedrático de Oftalmología de la Universidad de Castilla - La Mancha, Instituto Oftalmológico Alicante (VISSUM), Red Temática de Investigación Cooperativa (RTICS) en Oftalmología, Albacete, España. JoseMaria.Ruiz@uclm.es · ·Arch Soc Esp Oftalmol · Pubmed #19658051.

ABSTRACT: OBJECTIVE: Age related macular degeneration (ARMD) in its neovascular form is a serious disease which produces legal blindness in many patients with poor prognosis if left untreated. We intend to establish a clinical guide with the different therapeutic options that exist nowadays, which may help the ophthalmologists in their clinical practice. METHODS: A group of medical retina experts selected by SERV have evaluated the results of different published studies with the drugs currently available, obtaining an evidence-based consensus. Some recommendations have been established for diagnosis, treatment and monitoring of patients with neovascular ARMD. RESULTS: The intravitreal injection of ranibizumab at a dosage of 0.5 mg produces significant improvement of visual acuity in subfoveal lesions, according to data obtained from studies with the highest level of evidence. It should be considered as a first choice drug. The use of bevacizumab, a drug with not approved indication for intraocular use, nor for the treatment of neovascular ARMD can reach a result which is closer to the ones obtained with ranibizumab than to those obtained with photodynamic therapy (PDT) and pegaptanib. The use of intravitreal pegaptanib sodium in intravitreal injection at a dosage of 0.3 mg as a treatment for subfoveal lesions can obtain similar results to the TFD, but with a wider range of injuries. CONCLUSION: The results of the evidence-based studies are a good guide for the treatment of this disease.

25 Guideline Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. 2009

Amoaku, W / Anonymous7690604 / Anonymous7700604 / Anonymous7710604. ·Scientific Department, The Royal College of Ophthalmologists, Regent's Park, UK. Wma@nottingham.ac.uk · ·Eye (Lond) · Pubmed #18670458.

ABSTRACT: -- No abstract --